ClinicalTrials.Veeva

Menu

Neurological Features During COVID19 (NeuroSARS)

C

Centre d'Investigation Clinique et Technologique 805

Status

Unknown

Conditions

Encephalitis

Treatments

Other: Observation

Study type

Observational

Funder types

Other

Identifiers

NCT04460599
Brain COVID

Details and patient eligibility

About

Description of the neurological impairment: clinico-radiological and electrophysilogical correlations

Full description

Describe short and long term clinical radiological and electrophysilogical presentations of neurological damage central and peripheral SARS COV2 infection Describe the association between neurological, respiratory and dysautonomic Determine the prognosis of neurological damages to short and long term.

Enrollment

30 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • PCR SARS COV2 positive or CT Scan
  • Central neurological signs such as confusion, epilepsy, abnormal movement, pyramidal signs, motor or sensory deficit, involvement of cranial pairs (such as anomie or ageusia) or peripheral.
  • Dysautonomic signs such as hypotension or hypertension, bradycardia or tachycardia, hypothermia, SIADH not explained by therapy or a pathology other than SARS COV 2 infection

Exclusion criteria

  • Contraindication to performing an MRI scan
  • Minor
  • Pregnant woman
  • No follow-up possible at 6 months

Trial contacts and locations

1

Loading...

Central trial contact

Isabelle Bossard; David Orlikowski, MD PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems